Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire October 28, 2020

Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update

GlobeNewswire October 27, 2020

GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome

GlobeNewswire October 26, 2020

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

GlobeNewswire October 23, 2020

Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update

GlobeNewswire October 21, 2020

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

GlobeNewswire September 25, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire September 3, 2020

Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer

GlobeNewswire September 2, 2020

Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer

GlobeNewswire September 1, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 4, 2020

Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update

GlobeNewswire July 30, 2020

Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update

GlobeNewswire July 24, 2020

Ultragenyx Announces U.S. Commercial Launch of Dojolvi(TM) (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire July 22, 2020

Ultragenyx Announces U.S. FDA Approval of Dojolvi(TM) (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire June 30, 2020

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

GlobeNewswire June 18, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire May 28, 2020

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

GlobeNewswire May 21, 2020

Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

GlobeNewswire May 15, 2020

Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire May 13, 2020

Ultragenyx to Present at BofA Securities Global Health Care Conference

GlobeNewswire May 11, 2020